title: Early morning hyperglycemia in insulin-dependent diabetes: acute and sustained effects of cholinergic blockade.
abstract: Nocturnal release of GH has been shown to be related to the early morning rise in plasma glucose (PG) seen in insulin-dependent diabetes mellitus (IDDM). We have studied the effects of suppression of nocturnal GH release during a single night (acute study) and after nightly suppression for 1 week (chronic study). Changes in plasma glucose and counter-regulatory hormone concentrations were monitored in six IDDM patients during a constant overnight insulin infusion alone, after addition of the anticholinergic agent pirenzepine to cause acute GH suppression, and again on the seventh night of such treatment. In control experiments (infusion of insulin alone; 0.075 mU/kg.min) PG increased from (mean +/- SEM) 5.6 +/- 0.6 mmol/L at 2400 h to 11.1 +/- 1.3 mmol/L at 0900 h (P = 0.0024). Addition of pirenzepine (100 mg at 2200 h and again at 2400 h) in the acute study resulted in a PG change from 5.6 +/- 0.3 mmol/L at 2400 h to 8.4 +/- 1.4 mmol/L at 0900 h (P = 0.17). After pirenzepine administration at the same dose for 7 nights, PG increased from 4.7 +/- 0.6 mmol/L at 2400 h to 6.8 +/- 1.2 mmol/L at 0900 h (P = 0.11). Increases in PG during the study period were significantly less after chronic treatment than after acute treatment compared with changes on control nights. The nocturnal release of GH, which was demonstrated in all patients during the control nights, was suppressed in all patients during the acute study and in four of six patients during the chronic studies. We conclude that initial reduction of the early morning rise of PG in IDDM is associated with acute suppression of nocturnal GH release, and that the more significant sustained effect of anticholinergic GH suppression on the rise of PG may be associated with additional indirect effects on insulin clearance.
authors.affiliation: Diabetic Unit, University Hospital of Wales, Heath Park, Cardiff.
authors.forename: J A
authors.initials: JA
authors.lastname: Atiea
authors.forename: F
authors.initials: F
authors.lastname: Creagh
authors.forename: M
authors.initials: M
authors.lastname: Page
authors.forename: D R
authors.initials: DR
authors.lastname: Owens
authors.forename: M F
authors.initials: MF
authors.lastname: Scanlon
authors.forename: J R
authors.initials: JR
authors.lastname: Peters
mesh_terms: D000328:Adult; D001786:Blood Glucose / Q000032:analysis; D002940:Circadian Rhythm; D003922:Diabetes Mellitus, Type 1 / Q000097:blood / Q000150:complications*; D005934:Glucagon / Q000097:blood; D013006:Growth Hormone / Q000097:blood / Q000378:metabolism; D006801:Humans; D006854:Hydrocortisone / Q000097:blood; D006943:Hyperglycemia / Q000097:blood / Q000150:complications / Q000517:prevention & control*; D007328:Insulin / Q000008:administration & dosage; D008297:Male; D010276:Parasympatholytics / Q000008:administration & dosage*; D010890:Pirenzepine / Q000627:therapeutic use*
chemical_list: D001786:Blood Glucose; D007328:Insulin; D010276:Parasympatholytics; D010890:Pirenzepine; D013006:Growth Hormone; D005934:Glucagon; D006854:Hydrocortisone